Alzheimer’s

Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-BD01, a Phase 2A study of AL001 for bipolar disorder.  Lithium is a commonly prescribed drug for manic episodes in bipolar disorder type 1 and maintenance therapy for...

Eli Lilly And Co (NYSE: LLY) presented full results from the Phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease.  The data were shared at the Alzheimer's Association...

Senator Bernie Sanders urged the U.S. Department of Health and Human Services (HHS) to immediately address the exorbitant cost of Eisai Co Ltd (OTC: ESALY)/Biogen Inc (NASDAQ: BIIB) Alzheimer's treatment Leqembi (lecanemab).  Wednesday, the FDA released briefing...

Silo Pharma Inc. (NASDAQ: SILO), one of the biotech companies developing next-generation psychedelic therapeutics, obtained a new US patent covering IP for its drug candidate SPC-15’s research and development. The patent granted by the USPTO covers the use of biomarkers in...

Eli Lilly And Co (NYSE: LLY) expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid brain plaques can help patients. Lilly plans to release results from a trial of its...

The U.S. National Institute on Aging (NIA), part of the government's National Institutes of Health (NIH), aims to build an Alzheimer's research database. Alzheimer's Association Chief Science Officer Maria Carrillo said in an interview that the organization plans to apply for the NIA...

Alzamend Neuro Inc (NASDAQ: ALZN) has initiated a Phase 1/2A trial for its immunotherapy vaccine (ALZN002) to treat mild to moderate dementia of Alzheimer’s type. What Happened: The trial will assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002...

The Alzheimer's Association has launched a grassroots lobbying campaign while deploying 1,000 people, either patients or caring for someone with the disease, to meet with all 535 members of Congress across the U.S. and urge them to press Medicare program for the drugs starting with...

Biopharma stocks were not immune to the broader market downturn seen for much of 2022. The iShares Biotechnology ETF (NASDAQ: IBB), which is heavily weighted with large-cap biotech companies, has lost 13.2% compared to a steeper 27.8% pullback by the SPDR S&P Biotech (NYSE: XBI). What Happened...

MorphoSys AG's (NASDAQ: MOR) partner Roche Holdings AG (OTC: RHHBY) announced results from the GRADUATE I and II studies evaluating gantenerumab in mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia. The studies did not meet their...

Shares of Biogen Inc. (NASDAQ: BIIB) and Eli Lilly & Co. (NYSE: LLY) are rallying in premarket trading on Monday despite the negative broader market sentiment. Swiss pharma giant Roche Holding AG (OTC: RHHBY) announced that the two Phase 2 studies evaluating its gantenerumab in patients with...

One of the most-watched Alzheimer's therapies in the clinic, Biogen Inc (NASDAQ: BIIB)-Eisai Limited's (OTC: ESALY) experimental lecanemab reduced clinical decline on the scale by 27% compared to the placebo at 18 months in early Alzheimer's. In July 2022, the FDA...

Alzheimer's is a tough neurological disease to tackle, given the difficulty in diagnosing at an early stage, and the limited and effective treatment options currently available. New research has found that administering flu shots significantly reduces the risk of developing Alzheimer's,...

Centers for Medicare and Medicaid Services (CMS) finalized its decision to restrict coverage for Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug Aduhelm and other amyloid-targeted drugs to just patients participating in clinical trials. "Monoclonal antibodies...

Longeveron Inc (NASDAQ: LGVN) announced the publication of Phase 1 trial results of Lomecel-B on patients with mild Alzheimer's disease (AD) in the Alzheimer's & Dementia journal. The 33-subject trial met its primary endpoint, demonstrating that Lomecel-B was well...